Journal
DRUG DISCOVERY TODAY
Volume 20, Issue 12, Pages 1433-1438Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.drudis.2015.05.013
Keywords
-
Categories
Funding
- NCI NIH HHS [P30 CA016672] Funding Source: Medline
Ask authors/readers for more resources
The development of resources for clinical interpretation of cancer-associated genetic alterations has significantly lagged behind the technical developments enabling their detection in a time-and cost-efficient manner. The lack of scientific and informatics decision support for oncologists can lead to no action being taken or suboptimal therapeutic choices being made, which could affect the clinical outcome of a patient as well as convoluting research findings from clinical trials. In this article, we describe the precision oncology decision support (PODS) platform developed within The Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy (IPCT) at MD Anderson Cancer Center; the platform aims to bridge the gap between molecular alteration detection and identification of appropriate treatments.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available